Anne Pariser is the VP of Medical and Regulatory Affairs at Alltrna, the world’s first tRNA platform company seeking to develop tRNA as a therapy that could be used in thousands of genetic diseases. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH). During her tenure at ORDR, Dr. Pariser oversaw several research and development programs focused on advancing translational and clinical research into rare diseases. Some of these programs included the Rare Diseases Clinical Research Network (RDCRN), a network of research consortia focused on more than 200 different rare diseases, the Diagnostic Odyssey grants program intended to speed rare disease diagnosis, and the PaVe-GT gene therapy program, which seeks to develop gene therapies for several ultra-rare diseases at the same time using a platform approach, among other programs. Prior to ORDR, Dr. Pariser worked for more than 15 years at the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), where she predominantly focused on rare diseases drug review and most notably founded the Rare Diseases Program, which focused on developing regulatory science, policy, and processes intended to facilitate rare disease drug development and review. Dr. Pariser received her medical degree from Georgetown University School of Medicine and completed her Internal Medicine Internship and Residency at Georgetown University Medical Center. She continues to see patients at the Arlington Free Clinic in Arlington, Virginia USA.